Prostate Cancer - Results from #140

p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up. March 6, 2023

Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer. March 6, 2023

Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. March 6, 2023

HER2 as a potential therapeutic target on quiescent prostate cancer cells. March 6, 2023

Remodeling oncogenic transcriptomes by small molecules targeting NONO. March 6, 2023

Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers. March 5, 2023

Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. March 3, 2023

Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging. March 3, 2023

Multi-timepoint imaging with PSMA-targeted [18F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging. March 3, 2023

Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy. March 3, 2023

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. March 3, 2023

Retrospective Analysis of Clinical Outcomes of Stereotactic Body Radiation Therapy for Localized Prostate Cancer at an Asian Cancer Specialist Centre. March 2, 2023

A Comparison Between the Rates of Radiation Oncologist and Urologist Consultations in Men Diagnosed With Prostate Cancer in Northern Ontario, Canada. March 2, 2023

Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy. March 2, 2023

Dynamic changes in PSA levels predict prognostic outcomes in prostate cancer patients undergoing androgen -deprivation therapy: A multicenter retrospective analysis. March 2, 2023

Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415. March 2, 2023

Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden. March 2, 2023

Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with mCRPC with BRCA Gene Mutations March 1, 2023

ANZUP’s Pain-Free TRUS B Trial Wins the BJUI Global Prize 2023 for Article of the Year March 1, 2023

A comprehensive comparison between mpMRI of the prostate, MR-US fusion biopsy and whole mount histopathology. March 1, 2023

Page 8 of 1290